News


Positive Interim Clinical Results for VT-1161 to be Presented at the Infectious Diseases Society for Obstetrics and Gynecology Annual Meeting

Data from Planned Interim Analysis of Phase 2b Trial in Recurrent Vulvovaginal Candidiasis (RVVC) Demonstrate Potential Significant Advantages Over Current Treatment Paradigms


Viamet Pharmaceuticals, Inc. today announced that data from a planned interim analysis of REVIVE, a Phase 2b clinical trial of oral VT-1161 in recurrent vulvovaginal candidiasis (RVVC), will be presented by Dr. Jack Sobel, Dean, Department of Medicine, Wayne State University, at the Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) annual meeting, to be held August 11-13, in Annapolis, Maryland. VT-1161, the company’s lead product candidate, is a highly potent and selective inhibitor of fungal CYP51.